Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to find out if treatment with an intravitreal injection of
triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused
by panretinal photocoagulation treatment. At the present time, it is not known whether
intravitreal steroid or anti-vascular endothelial growth factor (anti-VEGF) injections are
beneficial in preventing vision loss after panretinal photocoagulation (PRP) treatment. It is
possible that one or both of the types of injections will prevent vision loss after PRP
treatment. However, it is not known whether the benefits of the injections will outweigh the
risks. It is possible that because of side effects, the injections may not be as good as
laser alone in treating the diabetic retinopathy.
Phase:
Phase 3
Details
Lead Sponsor:
Jaeb Center for Health Research
Collaborators:
Allergan Genentech, Inc. National Eye Institute (NEI)